One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
MustGrow Biologics Corp.
MGROF · OQB · Basic Materials · Agricultural Inputs
Current price
$0.26
52-week range
$0.22 - $0.68
Market cap
$18.52M
Balance sheet
Healthy
-19.97x Concerning
Net cash $2.75M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 1982.0% last year.
- Risk Return on equity was -222.5% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 9.2% (peer median: 26.1%).
What this company does
MustGrow Biologics Corp.
MustGrow Biologics Corp. creates natural products from mustard plants to help farmers protect their crops from diseases and pests. Their main income comes from selling these biological solutions, which is important because it offers a more sustainable way to farm compared to traditional chemicals.
How the company got here
MustGrow Biologics Corp. was founded in 2014 and originally known as Duport Capital Ltd. before changing its name in March 2018. The company's journey began with a vision to create natural, effective alternatives to synthetic pesticides and fertilizers. This led them to explore the potential of mustard plants, which naturally possess pest and disease deterrent properties. MustGrow has since focused on developing and commercializing these natural biological technologies, aiming to provide sustainable solutions for modern agriculture. Their business model centers on developing patented technology, securing regulatory approvals, and then bringing these products to market.
What it actually does
MustGrow Biologics Corp. is an agricultural biotechnology company that develops and sells natural, plant-based products for farming. Instead of using synthetic chemicals, which are increasingly being restricted or banned, MustGrow harnesses the power of mustard seeds to create solutions that help crops grow better and healthier. Their technologies are designed to improve soil health, protect plants from diseases and pests, and ultimately help farmers produce more food in a sustainable way.
TerraMG (Biocontrol)
TerraMG is MustGrow's flagship biocontrol technology, derived from mustard plants. It's essentially a natural pesticide designed to combat soil-borne diseases and pests that can harm various crops, including fruits and vegetables. This product also helps manage unwanted plant growth, making it suitable for organic farming and areas where certain chemical herbicides are banned. Think of it as a natural shield for the soil and plants, protecting them from harmful organisms and unwanted vegetation.
TerraSante (Biofertility)
TerraSante is MustGrow's biofertility technology, also derived from mustard plants. This product acts as an organic soil amendment, meaning it helps improve the quality and health of the soil. It provides nutrients that feed beneficial soil microbes, which in turn support plant growth and improve the soil's ability to retain water and nutrients. Essentially, TerraSante nourishes the soil, creating a better environment for crops to thrive and increasing their overall yield and health.
What management is betting on now
MustGrow's management is focused on expanding the commercialization of its patented mustard-derived technologies, TerraMG and TerraSante. They are actively pursuing regulatory approvals in key agricultural markets, particularly in the United States and Canada, to broaden the sales reach of these products. A significant part of their strategy involves forming partnerships with larger agricultural companies, like Bayer, to help with global distribution and regulatory processes. The company believes that the increasing global demand for sustainable and organic farming practices presents a major growth opportunity for their natural crop input solutions.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $0.26
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $2.7M - more cash than debt. Interest coverage -20.0x.
Net debt
$-2.75M
Interest coverage
-19.97x
MustGrow Biologics Corp.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
MGROF
BASELINE
MustGrow Biologics Corp.
Total debt $366.89K Interest coverage -19.97x This is the baseline the peer rows are being compared against.
Total debt $2.10M Interest coverage -89.39x Neither company has much profit cushion over interest right now.
Total debt $286.26M Interest coverage -1.90x Neither company has much profit cushion over interest right now.
Total debt $236.80M Interest coverage -0.03x Neither company has much profit cushion over interest right now.
What you should know
The case for and against MGROF
1 Reward
2 Risks
Rewards
-
Revenue grew 1982.0% last year.
Risks
-
Return on equity was -222.5% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 9.2% (peer median: 26.1%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-5.26x
P/B
5.13x
P/S
1.95x
EV/EBITDA
-3.44x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
23.6%
Operating margin
34.7%
Net margin
-58.5%
ROE
-222.5%
ROA
-42.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.10x
Current ratio
3.63x
Quick ratio
2.94x
Total debt
$366.89K
Total cash
$3.11M
Growth
How the business has been compounding
Revenue TTM
$6.77M
Revenue 5Y CAGR
985.5%
EPS TTM
-0.06
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-3.60M
Free CF TTM
$-3.60M
FCF margin
-53.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—